Pliant Therapeutics Liabilities 2024

Pliant Therapeutics Aktienanalyse

What does Pliant Therapeutics do?

Pliant Therapeutics Inc is a biopharmaceutical company located in South San Francisco, California. The company was founded in 2016 by a group of scientists specializing in the discovery of therapeutics for the treatment of fibrosis and cancer. The history of Pliant Therapeutics Inc begins with the discovery of proteins involved in the development of fibrosis. These proteins, known as integrins, play a key role in tissue repair and regeneration. However, when they are overactive, they can lead to an overproduction of connective tissue, resulting in fibrosis. Pliant Therapeutics Inc aims to develop innovative therapeutics for the treatment of fibrosis and cancer. The company utilizes an innovative business model based on the discovery and development of novel therapeutics targeting the regulation of integrins. The company specializes in various areas. One important focus is the research of therapeutics for the treatment of lung diseases such as idiopathic pulmonary fibrosis (IPF) and asthma. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit the fibrosis process and improve lung function. Another focus of Pliant Therapeutics Inc is the development of therapeutics for the treatment of connective tissue disorders, such as scleroderma and systemic lupus erythematosus (SLE). The company has also launched a program for the development of therapeutics for the treatment of cancer. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit tumor growth and improve the effectiveness of cancer drugs. Pliant Therapeutics Inc has several products in the pipeline, including PT004 for the treatment of lung diseases and PT001 for the treatment of scleroderma. PT004 is an inhalable drug that aims to inhibit the fibrosis process in the lungs. It is currently in Phase 2 of clinical development and has the potential to improve lung function in patients with idiopathic pulmonary fibrosis (IPF) and severe asthma. PT001 is an orally administered drug that targets the treatment of scleroderma. The drug is currently in preclinical development and has the potential to inhibit the fibrosis process in various organs. Overall, Pliant Therapeutics Inc has the potential to play a leading role in the discovery and development of novel therapeutics for the treatment of fibrosis and cancer. The company is well-funded and has an experienced team of scientists and managers specializing in the development of innovative therapeutics. Pliant Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Pliant Therapeutics's Liabilities

Pliant Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Pliant Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Pliant Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Pliant Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Pliant Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Pliant Therapeutics Stock

What is the level of liabilities of Pliant Therapeutics this year?

Pliant Therapeutics has a debt balance of 38.58 M USD this year.

What were the liabilities of Pliant Therapeutics compared to the previous year?

The liabilities of Pliant Therapeutics have increased by 3.43% increased compared to the previous year.

What are the consequences of high debt for investors of Pliant Therapeutics?

High liabilities can pose a risk for investors of Pliant Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Pliant Therapeutics?

Low liabilities mean that Pliant Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Pliant Therapeutics affect the company?

An increase in liabilities of Pliant Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Pliant Therapeutics affect the company?

A decrease in the liabilities of Pliant Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Pliant Therapeutics?

Some factors that can influence the liabilities of Pliant Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Pliant Therapeutics so important for investors?

The liabilities of Pliant Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Pliant Therapeutics take to modify the liabilities?

To change its liabilities, Pliant Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Pliant Therapeutics pay?

Over the past 12 months, Pliant Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pliant Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Pliant Therapeutics?

The current dividend yield of Pliant Therapeutics is .

When does Pliant Therapeutics pay dividends?

Pliant Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pliant Therapeutics?

Pliant Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Pliant Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pliant Therapeutics located?

Pliant Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pliant Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pliant Therapeutics from 5/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.

When did Pliant Therapeutics pay the last dividend?

The last dividend was paid out on 5/28/2024.

What was the dividend of Pliant Therapeutics in the year 2023?

In the year 2023, Pliant Therapeutics distributed 0 USD as dividends.

In which currency does Pliant Therapeutics pay out the dividend?

The dividends of Pliant Therapeutics are distributed in USD.